BEAT
HeartBeam, Inc.3.4400
+0.8100+30.8%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
118.49MP/E (TTM)
-Basic EPS (TTM)
-0.66Dividend Yield
0%Recent Filings
8-K
FDA rejects ECG software
HeartBeam received an FDA Not Substantially Equivalent letter on November 20, 2025, for its 12-Lead ECG Synthesis Software 510(k) application. The company backs its clinical data and plans FDA talks for resolution. Meanwhile, it's eyeing launch of its 3D ECG system, cleared in December 2024. FDA approval remains key.
10-Q
Q3 FY2025 results
HeartBeam posted a Q3 operating loss of $5.3M, up 4% y/y, while nine-month loss hit $15.8M, 6% worse y/y, driven by R&D jumping 13% q/q and 24% ytd on HeartBeam System development and stock-based comp. G&A fell 8% q/q and 15% ytd via cost cuts. Cash drained to $1.9M amid $11.1M nine-month operating burn, offset by $10.7M from February equity raise; no debt, $15.5M ATM remains. EPS checks out at $(0.15) on 34.4M shares. FDA-cleared device awaits 12L software nod. Going concern doubts linger. Competition from larger firms shadows path.
10-Q
Q2 FY2025 results
HeartBeam's Q2 FY2025 results show steady operating losses of $5.0M, flat year-over-year but up slightly quarter-on-quarter from Q1's $5.5M (derived), driven by ramped R&D spending on product development and headcount while G&A dipped on lower stock-based comp. Net loss edged to $5.0M from $5.0M last year, with EPS improving to $(0.15) from $(0.19) thanks to more shares outstanding; YTD net loss of $10.5M aligns with diluted shares of 32.2M, no anti-dilution flagged. Cash burn hit $7.9M YTD, offset by $10.7M from February's equity raise, leaving $5.1M in cash and equivalents at quarter-end—no debt, but liquidity falls short of 12-month runway per going concern note. FDA-cleared HeartBeam System advanced with VALID-ECG study's 93.4% diagnostic agreement and AccurKardia tie-up for automated reads. Yet competition from bigger players in cardiac monitoring looms large.
8-K
Annual meeting outcomes
HeartBeam, Inc. held its annual stockholder meeting on July 11, 2025, electing all nine director nominees and ratifying CBIZ CPAs P.C. as auditors for the fiscal year ending December 31, 2025. Shareholders approved amending the 2022 Equity Incentive Plan, boosting authorized shares by 3,000,000 to 11,900,000. This expands equity award capacity. Yet approval was narrow, with 61% in favor amid heavy broker non-votes.
10-Q
Q1 FY2025 results
HeartBeam's Q1 FY2025 results show operating expenses climbing 15% y/y to $5.5M, driven by a 44% jump in R&D to $3.5M from headcount growth and product development, while G&A dipped 15% to $2.0M on lower stock-based comp. This pushed the operating loss to $5.5M, up 15% y/y, with net loss at $5.5M or $(0.18) per diluted share on 30.4M weighted shares—anti-dilution kept basic and diluted equal. No revenue yet, but cash swelled to $8.2M including short-term investments, bolstered by $10.3M net from a February equity offering of 6.7M shares. The VALID-ECG study hit 93.4% diagnostic agreement in April, paving way for 12L software clearance. Liquidity supports milestones, yet funding needs loom large. Competition from larger players shadows progress.
IPO
Website
Employees
Sector
Industry
CBLL
CeriBell, Inc.
21.99+0.09
DH
Definitive Healthcare Corp.
2.29-0.01
HNGE
Hinge Health, Inc.
48.41-0.09
HSCS
HeartSciences Inc.
2.31-0.16
HTFL
Heartflow, Inc.
26.47+0.84
IRTC
iRhythm Technologies, Inc.
167.90-1.10
OHCFF
LIGHT AI INC.
0.11+0.00
ONMD
OneMedNet Corp
1.41+0.17
RMHI
Retrieve Medical Holdings Inc
2.82+0.02
VSEE
VSee Health, Inc.
0.45-0.02